<SEC-DOCUMENT>0001193125-20-276994.txt : 20201026
<SEC-HEADER>0001193125-20-276994.hdr.sgml : 20201026
<ACCEPTANCE-DATETIME>20201026163403
ACCESSION NUMBER:		0001193125-20-276994
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20201026
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201026
DATE AS OF CHANGE:		20201026

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adicet Bio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38359
		FILM NUMBER:		201261071

	BUSINESS ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	resTORbio, Inc.
		DATE OF NAME CHANGE:	20171024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d71827d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:acet="http://www.adicetbio.com/20201026" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2020-10-26_to_2020-10-26">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2020-10-26_to_2020-10-26">0001720580</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="acet-20201026.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2020-10-26_to_2020-10-26"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-10-26</xbrli:startDate> <xbrli:endDate>2020-10-26</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2020-10-26_to_2020-10-26">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2020-10-26_to_2020-10-26" format="ixt:datemonthdayyearen">October&#160;26, 2020</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2020-10-26_to_2020-10-26">Adicet Bio, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2020-10-26_to_2020-10-26" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2020-10-26_to_2020-10-26">001-38359</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2020-10-26_to_2020-10-26">81-3305277</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2020-10-26_to_2020-10-26">500 Boylston Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2020-10-26_to_2020-10-26">13th Floor</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2020-10-26_to_2020-10-26">Boston</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2020-10-26_to_2020-10-26">MA</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2020-10-26_to_2020-10-26">02116</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area <span style="white-space:nowrap">code:&#160;<ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2020-10-26_to_2020-10-26">(857)</ix:nonNumeric>&#160;<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2020-10-26_to_2020-10-26">315-5528</ix:nonNumeric></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2020-10-26_to_2020-10-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2020-10-26_to_2020-10-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2020-10-26_to_2020-10-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2020-10-26_to_2020-10-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2020-10-26_to_2020-10-26">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2020-10-26_to_2020-10-26">ACET</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2020-10-26_to_2020-10-26" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2020-10-26_to_2020-10-26" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2020-10-26_to_2020-10-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;5.02.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;26, 2020, Adicet Bio, Inc. (the &#8220;Company&#8221;) announced the appointment of Don Healey, Ph.D., as Chief Technology Officer of the Company, effective October&#160;26, 2020 (the &#8220;Effective Date&#8221;). In connection with Dr.&#160;Healey&#8217;s appointment, the Company has entered into an employment agreement with Dr.&#160;Healey, dated September&#160;24, 2020 (the &#8220;Employment Agreement&#8221;), pursuant to which Dr.&#160;Healey will serve as Chief Technology Officer of the Company, effective as of the Effective Date. Dr.&#160;Healey&#8217;s Employment Agreement provides for &#8220;at will&#8221; employment. Pursuant to Dr.&#160;Healey&#8217;s Employment Agreement, Dr.&#160;Healey is entitled to an annual base salary of $385,000. Commencing in calendar year 2021, Dr.&#160;Healey is also eligible for annual incentive compensation targeted at 40% of his base salary, provided that any incentive compensation for calendar year 2020 will be prorated based on the Effective Date. Dr.&#160;Healey&#8217;s Employment Agreement also provides for a monthly travel stipend and relocation reimbursement. Dr.&#160;Healey is eligible to participate in the employee benefit plans generally available to full-time employees, subject to the terms of those plans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Employment Agreement further provides that the Board will grant Dr.&#160;Healey an inducement <span style="white-space:nowrap">non-qualified</span> stock option to purchase up to 166,605 shares of common stock. Twenty-five percent of the shares underlying such option shall vest on October&#160;26, 2021 and the remainder of such shares shall vest in <span style="white-space:nowrap">thirty-six</span> equal monthly installments thereafter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Dr.&#160;Healey&#8217;s Employment Agreement, if Dr.&#160;Healey&#8217;s employment is terminated by the Company without cause or by Dr.&#160;Healey for good reason within <span style="white-space:nowrap">the&#160;twelve-month&#160;period</span> following a change in control (as such terms are defined in his Employment Agreement and subject to the terms and conditions therein), then Dr.&#160;Healey will be entitled to (1)&#160;a lump sum cash payment equal to the sum of his then-current annual base salary (or his base salary in effect immediately prior to the change in control, if higher) and his target bonus for the then-current year (or his target bonus in effect immediately prior to the change in control, if higher), (2) any unpaid bonus earned for the year preceding the date of Dr.&#160;Healey&#8217;s employment termination, payable at the time it would otherwise have been paid had his employment not terminated, (3)&#160;full acceleration of all time-based stock options and other time-based stock awards held by Dr.&#160;Healey, and (4)&#160;monthly cash payments equal to the monthly employer contribution that the Company would have made to provide health insurance for Dr.&#160;Healey and any covered dependents for up to twelve&#160;months. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to such agreement, a copy of which is attached to this Current Report as Exhibit 99.1 and incorporated herein by reference. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Dr.&#160;Healey&#8217;s appointment as Chief Technology Officer, the Company issued a press release on October&#160;26, 2020 titled &#8220;Adicet Appoints Don Healey, Ph.D., as Chief Technology Officer,&#8221; a copy of which is filed herewith as Exhibit 99.2 and is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&#160;Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d71827dex991.htm">Employment Agreement, dated September 24, 2020. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d71827dex992.htm">Press Release, dated October&#160;26, 2020. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:87%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Adicet Bio, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chen Schor</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-style:italic">Name:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">Chen Schor</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-style:italic">Title:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">President and Chief Executive Officer</span></td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: October&#160;26, 2020 </p>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d71827dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Employment Agreement (&#147;Agreement&#148;) is made between Adicet Therapeutics, Inc., a Delaware corporation (the &#147;Company&#148;),
and Don Healey (the &#147;Executive&#148;) and is dated as of September&nbsp;24, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to employ the
Executive and the Executive desires to be employed by the Company beginning on October&nbsp;26, 2020 or such other date as may be mutually agreed (the &#147;Effective Date&#148;) on the terms contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE,<I> </I>in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employment</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Term</U>. The term of this Agreement shall commence on the Effective Date and continue until terminated in
accordance with the provisions hereof (the &#147;Term&#148;). The Executive&#146;s employment with the Company shall be &#147;at will,&#148; meaning that the Executive&#146;s employment may be terminated by the Company or the Executive at any time
and for any reason subject to the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Position and Duties</U>. The Executive shall
serve as the Chief Technology Officer of the Company and shall have such powers and duties as may from time to time be prescribed by the Chief Executive Officer of the Company (the &#147;CEO&#148;). The Executive shall devote his full working time
and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Governance Committee of the Board of Directors of Adicet Bio, Inc. (the
&#147;Governance Committee&#148; of the &#147;Board&#148; of &#147;Parent&#148;), or engage in religious, charitable or other community activities as long as such services and activities do not interfere with the Executive&#146;s performance of his
duties to the Parent and the Company as provided in this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation and Related Matters</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Base Salary</U>. The Executive&#146;s initial base salary shall be paid at the rate of $385,000 per year.
The Executive&#146;s base salary shall be subject to periodic review by<B> </B>the Compensation Committee of the Board (the &#147;Compensation Committee&#148;). The base salary in effect at any given time is referred to herein as &#147;Base
Salary.&#148; The Base Salary shall be payable in a manner that is consistent with the Company&#146;s usual payroll practices for executive officers. The Executive&#146;s salary and any other cash compensation may be provided through TriNet, Inc. or
another professional employer organization (a &#147;PEO&#148;). As a result of the Company&#146;s arrangement with the PEO, the PEO will be considered the Executive&#146;s employer of record for these purposes for so long as that arrangement exists.
While the PEO will have responsibility for the functions above, the Company retains responsibility for overseeing the Executive&#146;s work and reviewing the Executive&#146;s performance, among other functions. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Incentive Compensation</U>. The Executive shall be eligible to
receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Executive&#146;s initial target annual incentive compensation shall be forty (40)&nbsp;percent of the Executive&#146;s Base Salary;
provided that any incentive compensation for calendar year 2020 will be prorated based on the Effective Date. The target annual incentive compensation in effect at any given time is referred to herein as &#147;Target Bonus.&#148; The actual amount
of the Executive&#146;s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time
to time. Except as otherwise provided herein, as may be provided by the Board or the Compensation Committee or as may otherwise be set forth in the applicable incentive compensation plan the Executive must be employed by the Company on the day such
incentive compensation is paid in order to earn or receive any incentive compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Commuting and
Lodging Expenses; Relocation Reimbursement</U>. The Company will provide a fully taxable stipend of $6,000 per month, less applicable taxes and withholdings (the &#147;Commuting Stipend&#148;), which may be used for reasonable travel and lodging
expenses related to Executive&#146;s travel back and forth from Anderson, Texas to the San Francisco Bay Area to provide services under this Agreement (for up to six (6)&nbsp;months from the Effective Date). The Executive agrees that as a material
term of this Agreement he will relocate permanently to the San Francisco Bay Area (the &#147;Permanent Relocation&#148;) no later than the six (6)&nbsp;month anniversary of the Effective Date. To assist in the Permanent Relocation, the Company will
make a fully taxable lump sum payment to the Executive to cover Reasonable Moving Expenses (as defined below) of up to a maximum of $75,000 (the &#147;Relocation Reimbursement&#148;); <I>provided</I>, however, that if the Executive is terminated for
Cause (as defined below) or resigns other than for Good Reason (as defined below) within six (6)&nbsp;months of such Relocation Reimbursement, the Executive shall repay to the Company such Relocation Reimbursement. The Relocation Reimbursement shall
be paid within thirty (30)&nbsp;days after the Executive has submitted to the Company such documentation supporting such reimbursement as is required under the Company&#146;s generally applicable policies regarding same. Following the Permanent
Relocation, the Executive shall no longer be eligible for the Commuting Stipend. For purposes of this Agreement, &#147;Reasonable Moving Expenses&#148; shall mean the Executive&#146;s actual out of pocket expenses (but not, for the avoidance of
doubt, any loss on sale, real estate-related taxes or attorneys&#146; fees) related to (A)&nbsp;the disposition of the Executive&#146;s then current principal residence, (B)&nbsp;relocation of the Executive&#146;s principal residence to a location
within two hundred (200)&nbsp;miles of the Executive&#146;s then current principal place of work for the Company, (C)&nbsp;housing-hunting trips related to such relocation and (D)&nbsp;other moving expenses incurred to relocate the Executive&#146;s
household goods, furnishings, and personal belongings from the Executive&#146;s then current residence to the Executive&#146;s new residence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Expenses</U>. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses
incurred by the Executive during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Benefits</U>. The Executive shall be eligible to participate in or receive benefits under the
Company&#146;s employee benefit plans in effect from time to time, subject to the terms of such plans. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Paid Time Off</U>. The Company&#146;s current paid time off
policy for executives is flexible and paid time off may be taken at such times and intervals as the Executive may determine, subject to the business needs of the Company and the terms and conditions of any policies as may be in effect from time to
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Equity</U>.<B> </B>As a material inducement to the Executive&#146;s acceptance of this offer, subject
to approval of the Board or the Compensation Committee, following the Effective Date the Executive shall be granted an option to purchase approximately 0.85&nbsp;percent of issued and outstanding shares of Parent Common Stock at the Effective Date
at a per share exercise price determined on the grant date in accordance with the Company&#146;s equity grant policies, with 25&nbsp;percent of the shares underlying the option vesting on the first anniversary of the Effective Date and the remainder
of the shares underlying the option vesting thereafter in 36 equal monthly installments until the fourth anniversary of the Effective Date, subject to the Executive&#146;s continued service with the Company through each such vesting date. This grant
will be subject to the terms of a <FONT STYLE="white-space:nowrap">non-shareholder</FONT> approved equity incentive plan to be approved by the Board pursuant to the &#147;inducement exception&#148; provided under NASDAQ Listing Rule
5635(c)(4).&nbsp;We anticipate that the terms of this plan and the applicable stock option agreement will be similar to the terms of the Company&#146;s other equity incentive plan and standard form of stock option agreement thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>. The Company shall indemnify the Executive to the extent that its officers, directors and
employees are entitled to indemnification pursuant to the Company&#146;s Certificate of Incorporation and Bylaws for any acts or omissions by reason of being an officer or employee of the Company as of the Effective Date. At all times during the
Employment Term, the Company shall maintain in effect a director and officers liability insurance policy with the Executive as a covered officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. The Executive&#146;s employment hereunder may be terminated without any breach of this Agreement
under the following circumstances: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Death</U>. The Executive&#146;s employment hereunder shall terminate
upon death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Disability</U>. The Company may terminate the Executive&#146;s employment if the Executive is
disabled and unable to perform or expected to be unable to perform the essential functions of the Executive&#146;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need
not be consecutive) in any <FONT STYLE="white-space:nowrap">12-month</FONT> period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive&#146;s
then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the
Executive or the Executive&#146;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of
the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company&#146;s determination of
such issue shall be binding on the Executive. Nothing in this Section&nbsp;3(b) shall be construed to waive the Executive&#146;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C.
&#167;2601 <I>et seq</I>. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 <I>et seq.</I> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by the Company for Cause</U>. The Company may
terminate the Executive&#146;s employment hereunder for Cause. For purposes of this Agreement, &#147;Cause&#148; shall mean: (i)&nbsp;conduct by the Executive constituting a material act of misconduct in connection with the performance of his
duties, including, without limitation, misappropriation of funds or property of the Company, Parent or any of its or their subsidiaries or affiliates other than the occasional, customary and de minimis use of Company or Parent property for personal
purposes; (ii)&nbsp;the commission by the Executive of acts satisfying the elements of (A)&nbsp;any felony or (B)&nbsp;a misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;any misconduct by the Executive, regardless of
whether or not in the course of the Executive&#146;s employment, that would reasonably be expected to result in material injury or reputational harm to the Company, Parent or any of its or their subsidiaries or affiliates if the Executive were to
continue to be employed in the same position; (iv)&nbsp;continued willful nonperformance by the Executive of his material duties hereunder (other than by reason of the Executive&#146;s physical or mental illness, incapacity or disability) which, to
the extent it is curable by the Executive, is not cured within thirty (30)&nbsp;after written notice thereof is given to the Executive by the CEO; (v)&nbsp;a breach by the Executive of the Restrictive Covenants Agreement or any of the provisions
contained in Section&nbsp;8 of this Agreement; (vi)&nbsp;a material violation by the Executive of the Company&#146;s or Parent&#146;s written employment policies; or (vii)&nbsp;failure to cooperate with a bona fide internal investigation or an
investigation by regulatory or law enforcement authorities, after being instructed by the Company or Parent to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or
the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination by the Company without Cause</U>. The Company may terminate the Executive&#146;s employment
hereunder at any time without Cause. Any termination by the Company of the Executive&#146;s employment under this Agreement which does not constitute a termination for Cause under Section&nbsp;3(c) and does not result from the death or disability of
the Executive under Section&nbsp;3(a) or (b)&nbsp;shall be deemed a termination without Cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
by the Executive</U>. The Executive may terminate his employment hereunder at any time for any reason, including for Good Reason. For purposes of this Agreement, &#147;Good Reason&#148; shall mean that the Executive has complied with the &#147;Good
Reason Process&#148; (hereinafter defined) following the occurrence of any of the following events: (i)&nbsp;a material diminution in the Executive&#146;s responsibilities, authority or duties <I>provided </I>changes to the Executive&#146;s
responsibilities, authority or duties prior to a Change in Control that are made in the good faith discretion of the Company&#146;s CEO as part of the Company&#146;s evolving business needs and strategy shall not be a Good Reason occurrence;
(ii)&nbsp;a material diminution in the Executive&#146;s Base Salary except for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> salary reductions based on the Company&#146;s or Parent&#146;s financial
performance similarly affecting all or substantially all senior management employees of the Company or Parent; (iii)&nbsp;a material change in the geographic location at which the Executive provides services to the Company such that there is an
increase of at least thirty (30)&nbsp;miles of driving distance to such location from the Executive&#146;s principal residence as of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such change; or (iv)&nbsp;the material breach of this Agreement by the Company. &#147;Good Reason Process&#148; shall mean that (i)&nbsp;the Executive reasonably determines in good faith that a
&#147;Good Reason&#148; condition has occurred; (ii)&nbsp;the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii)&nbsp;the Executive
cooperates in good faith with the Company&#146;s efforts, for a period not less than 30 days following such notice (the &#147;Cure Period&#148;), to remedy the condition; (iv)&nbsp;notwithstanding such efforts, the Good Reason condition continues to
exist; and (v)&nbsp;the Executive terminates his employment within 180 days after the end of the Cure Period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Matters Related to Termination</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Termination</U>. Except for termination as specified in Section&nbsp;3(a), any termination of the
Executive&#146;s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a &#147;Notice of Termination&#148; shall mean a
notice which shall indicate the specific termination provision in this Agreement relied upon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Date of
Termination</U>. &#147;Date of Termination&#148; shall mean: (i)&nbsp;if the Executive&#146;s employment is terminated by death, the date of death; (ii)&nbsp;if the Executive&#146;s employment is terminated on account of disability under
Section&nbsp;3(b) or by the Company for Cause under Section&nbsp;3(c), the date on which Notice of Termination is given; (iii)&nbsp;if the Executive&#146;s employment is terminated by the Company without Cause under Section&nbsp;3(d), the date on
which a Notice of Termination is given or the date otherwise specified by the Company in the Notice of Termination; (iv)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) other than for Good Reason, 30
days after the date on which a Notice of Termination is given, and (v)&nbsp;if the Executive&#146;s employment is terminated by the Executive under Section&nbsp;3(e) for Good Reason, the date on which a Notice of Termination is given after the end
of the Cure Period. Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination
by the Company for purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Accrued Obligations</U>. If the Executive&#146;s employment
with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to the Executive&#146;s<B> </B>authorized representative or estate)&nbsp;(i) any Base Salary earned through the Date of Termination;
(ii)&nbsp;unpaid expense reimbursements (subject to, and in accordance with, Sections 2(c)-(d) of this Agreement); and (iii)&nbsp;any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of
Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the &#147;Accrued Obligations&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Resignation of All Other Positions</U>. To the extent applicable, the Executive shall be deemed to have resigned
from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination of the Executive&#146;s employment for any reason. The Executive shall execute any
documents in reasonable form as may be requested to confirm or effectuate any such resignations. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severance Pay and Benefits Upon Termination by the Company
without Cause or by the Executive for Good Reason Outside the Change in Control Period</U>. If the Executive&#146;s employment is terminated by the Company without Cause as provided in Section&nbsp;3(d) or the Executive terminates employment for
Good Reason as provided in Section&nbsp;3(e), in each case outside of the Change in Control Period (as defined below), then, in addition to the<B> </B>Accrued Obligations, subject to the Executive signing a separation agreement containing, among
other provisions, a general release of claims in favor of the Company and related persons and entities, including the PEO, a reaffirmation of the Executive&#146;s Continuing Obligations (as defined below), confidentiality, return of property and <FONT
STYLE="white-space:nowrap">non-disparagement,</FONT> in a form and manner satisfactory to the Company (the &#147;Separation Agreement and Release&#148;) and the Separation Agreement and Release becoming irrevocable and fully effective, all within 60
days after the Date of Termination (or such shorter time period provided in the Separation Agreement and Release): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay the Executive an amount equal to<B> </B>nine (9)&nbsp;months of the Executive&#146;s Base
Salary (the &#147;Severance Amount&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay any unpaid bonus earned for the year
preceding the date of Executive&#146;s employment termination, payable at the time it otherwise would have been paid had the Executive&#146;s employment with the Company not terminated; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;subject to the Executive&#146;s copayment of premium amounts at the applicable active employees&#146; rate and the
Executive&#146;s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), the Company shall pay to the Executive a monthly cash payment (including a gross up payment
to account for applicable taxes and withholdings) equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive and covered dependents if the Executive had remained employed by the Company
until the earliest of (A)&nbsp;the nine (9)&nbsp;month anniversary of the Date of Termination; (B)&nbsp;the date that the Executive becomes eligible for group medical plan benefits under any other employer&#146;s group medical plan; or (C)&nbsp;the
cessation of the Executive&#146;s health continuation rights under COBRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under Section&nbsp;5(a) and (c), to the extent taxable,
shall be paid out in substantially equal installments in accordance with the Company&#146;s payroll practice over nine (9)&nbsp;months commencing within 60<B> </B>days after the Date of Termination; provided, however, that if the <FONT
STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148;
within the meaning of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), shall begin to be paid in the second calendar year by the last day of such <FONT STYLE="white-space:nowrap">60-day</FONT> period;
provided, further, that the initial payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is
intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason
within the Change in Control Period</U>. The provisions of this Section&nbsp;6 shall apply in lieu of, and expressly supersede, the provisions of Section&nbsp;5 if (i)&nbsp;the Executive&#146;s employment is terminated either (a)&nbsp;by the Company
without Cause as provided in Section&nbsp;3(d), or (b)&nbsp;by the Executive for Good Reason as provided in Section&nbsp;3(e), and (ii)&nbsp;the Date of Termination occurs on or within 12 months after the occurrence of the first event constituting a
Change in Control (such period, the &#147;Change in Control Period&#148;) following the Effective Date. These provisions shall terminate and be of no further force or effect after the Change in Control Period. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If the Executive&#146;s employment is terminated by the Company
without Cause as provided in Section&nbsp;3(d) or the Executive terminates employment for Good Reason as provided in Section&nbsp;3(e) and in each case the Date of Termination occurs during the Change in Control Period, then, in addition to the
Accrued Obligations, and subject to the signing of the Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release
but in no event more than 60 days after the Date of Termination: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay the
Executive a lump sum in cash in an amount equal to<B> </B>one (1)&nbsp;times the sum of (A)&nbsp;the Executive&#146;s then-current Base Salary (or the Executive&#146;s Base Salary in effect immediately prior to the Change in Control, if higher) plus
(B)&nbsp;the Executive&#146;s Target Bonus for the then-current year (or the Executive&#146;s Target Bonus in effect immediately prior to the Change in Control, if higher) and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay any unpaid bonus earned for the year preceding the date of Executive&#146;s
employment termination, payable at the time it otherwise would have been paid had the Executive&#146;s employment with the Company not terminated, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;notwithstanding anything to the contrary in any applicable option agreement or other stock-based
award agreement, all stock options and other stock-based awards held by the Executive that are subject solely to time-based vesting (the &#147;Time-Based Equity Awards&#148;) shall immediately accelerate and become fully vested and exercisable or
nonforfeitable as of the later of (i)&nbsp;the Date of Termination or (ii)&nbsp;the effective date of the Separation Agreement and Release (the &#147;Accelerated Vesting Date&#148;), provided in order to effectuate the accelerated vesting
contemplated by this subsection, the unvested portion of the Executive&#146;s options that would otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A)&nbsp;the effective date of the Separation Agreement Release
(at which time acceleration will occur), or (B)&nbsp;the date that the Separation Agreement and Release can no longer become fully effective (at which time the unvested Time-Based Equity Awards will be terminated or forfeited). Notwithstanding the
foregoing, no additional time-based vesting of the Time-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;subject to the Executive&#146;s copayment of premium amounts at the applicable active
employees&#146; rate and the Executive&#146;s proper election to receive benefits under COBRA, the Company shall pay to the Executive a monthly cash payment (including a gross up payment to account for applicable taxes and withholdings) equal to the
monthly employer contribution that the Company would have made to provide health insurance to the Executive and covered dependents if the Executive had remained </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
employed by the Company until the earliest of (A)&nbsp;the twelve (12)&nbsp;month anniversary of the Date of Termination; (B)&nbsp;the date that the Executive becomes eligible for group medical
plan benefits under any other employer&#146;s group medical plan; or (C)&nbsp;the cessation of the Executive&#146;s health continuation rights under COBRA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts payable under this Section&nbsp;6(a), to the extent taxable, shall be paid or commence to be paid within 60 days after the Date of Termination;
provided, however, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as
<FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such <FONT
STYLE="white-space:nowrap">60-day</FONT> period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Limitation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any
compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with
Section&nbsp;280G of the Code, and the applicable regulations thereunder (the &#147;Aggregate Payments&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then the Aggregate Payments shall be reduced (but not below
zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section&nbsp;4999 of the Code; provided that such reduction shall only occur if it would
result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following
order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section&nbsp;280G of the Code: (1)&nbsp;cash payments not
subject to Section&nbsp;409A of the Code; (2)&nbsp;cash payments subject to Section&nbsp;409A of the Code; (3)&nbsp;equity-based payments and acceleration; and <FONT STYLE="white-space:nowrap">(4)&nbsp;non-cash</FONT> forms of benefits; provided
that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or
(c)&nbsp;shall be reduced before any amounts that are subject to calculation under Treas. Reg. <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q&amp;A-24(b)</FONT> or (c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Section&nbsp;6(b), the &#147;After Tax Amount&#148; means the amount of the
Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#146;s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive
shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal
rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The determination as to whether a reduction in
the Aggregate Payments shall be made pursuant to Section&nbsp;6(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the &#147;Accounting Firm&#148;), which shall provide detailed supporting calculations both to
the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the
Company and the Executive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. For purposes of this Section&nbsp;6, the following terms shall
have the following meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Change in Control&#148; shall mean any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;any &#147;person,&#148; as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended (the &#147;Act&#148;), any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of Parent or any of its subsidiaries), together with all
&#147;affiliates&#148; and &#147;associates&#148; (as such terms are defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Act) of such person, shall become the &#147;beneficial owner&#148; (as such term is defined in Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Act), directly or indirectly, of securities of Parent representing 50&nbsp;percent or more of the combined voting power of Parent&#146;s then outstanding securities having the right to vote in an
election of the Board (&#147;Voting Securities&#148;) (in such case other than as a result of an acquisition of securities directly from Parent); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the date a majority of the members of the Board is replaced during any <FONT
STYLE="white-space:nowrap">12-month</FONT> period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the consummation of (A)&nbsp;any consolidation or merger of Parent where the stockholders of
Parent, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Act), directly or
indirectly, shares representing in the aggregate more than 50&nbsp;percent of the voting shares of Parent issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B)&nbsp;any sale or other
transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a &#147;Change in Control&#148; shall not be deemed to have occurred for purposes of the foregoing clause
(i)&nbsp;solely as the result of an acquisition of securities by Parent which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to
50&nbsp;percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting
Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from Parent) and immediately thereafter beneficially owns 50&nbsp;percent or more of the combined voting
power of all of the then outstanding Voting Securities, then a &#147;Change in Control&#148; shall be deemed to have occurred for purposes of the foregoing clause (i). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Section 409A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#146;s separation from
service within the meaning of Section&nbsp;409A of the Code, the Company determines that the Executive is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit
that the Executive becomes entitled to under this Agreement or otherwise on account of the Executive&#146;s separation from service would be considered deferred compensation otherwise subject to the 20&nbsp;percent additional tax imposed pursuant to
Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A)&nbsp;six months and one
day after the Executive&#146;s separation from service, or (B)&nbsp;the Executive&#146;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a
<FONT STYLE="white-space:nowrap">catch-up</FONT> payment covering amounts that would otherwise have been paid during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;All
<FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All
reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of <FONT
STYLE="white-space:nowrap">in-kind</FONT> benefits provided or reimbursable expenses incurred in one taxable year shall not affect the <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement
in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not subject to liquidation or exchange for
another benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any payment or benefit described in this Agreement constitutes <FONT
STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#146;s termination of employment, then such payments
or benefits shall be payable only upon the Executive&#146;s &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury
Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The parties intend that this
Agreement will be administered in accordance with Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so
that all payments hereunder comply with Section&nbsp;409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all related
rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company makes no representation or warranty and shall have no
liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Continuing Obligations</U>.<U> </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictive Covenants Agreement</U>. As a condition of employment, the Executive is required to enter into the
Employee Confidentiality, Assignment and Nonsolicitation Agreement, attached hereto as <U>Exhibit A</U> (the &#147;Restrictive Covenants Agreement&#148;).<B> </B>For purposes of this Agreement, the obligations in this Section&nbsp;8 and those that
arise in the Restrictive Covenants Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#147;Continuing Obligations.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Third-Party Agreements and Rights</U>. The Executive hereby confirms that the Executive is not bound by the
terms of any agreement with any previous employer or other party which restricts in any way the Executive&#146;s use or disclosure of information, other than confidentiality restrictions (if any), or the Executive&#146;s engagement in any business.
The Executive represents to the Company that the Executive&#146;s execution of this Agreement, the Executive&#146;s employment with the Company and the performance of the Executive&#146;s proposed duties for the Company will not violate any
obligations the Executive may have to any such previous employer or other party. In the Executive&#146;s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any such
previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of <FONT STYLE="white-space:nowrap">non-public</FONT> information belonging to or obtained from any such
previous employment or other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation and Regulatory Cooperation</U>. During and after the
Executive&#146;s employment, the Executive shall cooperate fully with the Company in (i)&nbsp;the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate
to events or occurrences that transpired while the Executive was employed by the Company, and (ii)&nbsp;the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or information.
The Executive&#146;s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a
witness on behalf of the Company at mutually convenient times. During and after the Executive&#146;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local
regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the Executive&#146;s performance of obligations pursuant to this Section&nbsp;8(c). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Relief</U>. The Executive agrees that it would be difficult to
measure any damages caused to the Company which might result from any breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly<B>,</B> the Executive
agrees that if the Executive breaches, or proposes to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to
restrain any such breach without showing or proving any actual damage to the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration of
Disputes</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration Generally</U>. Any controversy or claim arising out of or relating to this
Agreement or the breach thereof or otherwise arising out of the Executive&#146;s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination or retaliation, whether based on race,
religion, national origin, sex, gender, age, disability, sexual orientation, or any other protected class under applicable law) shall, to the fullest extent permitted by law, be settled by arbitration in any forum and form agreed upon by the parties
or, in the absence of such an agreement, under the auspices of JAMS in San Francisco, California in accordance with the JAMS Employment Arbitration Rules, including, but not limited to, the rules and procedures applicable to the selection of
arbitrators. The Executive understands that the Executive may only bring such claims in the Executive&#146;s individual capacity, and not as a plaintiff or class member in any purported class proceeding or any purported representative proceeding.
The Executive further understands that, by signing this Agreement, the Company and the Executive are giving up any right they may have to a jury trial on all claims they may have against each other. Judgment upon the award rendered by the arbitrator
may be entered in any court having jurisdiction thereof. This Section&nbsp;9 shall be specifically enforceable. Notwithstanding the foregoing, this Section&nbsp;9 shall not preclude either party from pursuing a court action for the sole purpose of
obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate, including without limitation relief sought under the Restrictive Covenants Agreement; provided that any other relief shall be
pursued through an arbitration proceeding pursuant to this Section&nbsp;9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration Fees and Costs</U>.
The Executive shall be required to pay an arbitration fee to initiate any arbitration equal to what the Executive would be charged as a first appearance fee in court. The Company shall advance the remaining fees and costs of the arbitrator. However,
to the extent permissible under the law, and following the arbitrator&#146;s ruling on the matter, the arbitrator may rule that the arbitrator&#146;s fees and costs be distributed in an alternative manner. Each party shall pay its own costs and
attorneys&#146; fees, if any. If, however, any party prevails on a statutory or contractual claim that affords the prevailing party attorneys&#146; fees (including pursuant to this Agreement), the arbitrator may award attorneys&#146; fees to the
prevailing party to the extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent to Jurisdiction</U>. The parties hereby consent to
the jurisdiction of the state and federal courts of the<B> </B>State of California. Accordingly, with respect to any such court action, the Executive (a)&nbsp;submits to the exclusive personal jurisdiction of such courts; (b)&nbsp;consents to
service of process; and (c)&nbsp;waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>. This Agreement constitutes the entire
agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, including the Prior Agreement, provided that the Restrictive Covenants Agreement remains
in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding; Tax Effect</U>. All payments made by the Company to the Executive
under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any
adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors and Assigns</U>. Neither the Executive nor the Company may make any assignment of this Agreement or
any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement (including the Restrictive Covenants Agreement)
without the Executive&#146;s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into which the Company merges or to whom it transfers all or substantially all of its
properties or assets; provided further that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then the Executive shall not be entitled to any
payments, benefits or vesting pursuant to Section&nbsp;5 or pursuant to Section&nbsp;6 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon the Executive and the Company, and each
of the Executive&#146;s and the Company&#146;s respective successors, executors, administrators, heirs and permitted assigns. In the event of the Executive&#146;s death after the Executive&#146;s termination of employment but prior to the completion
by the Company of all payments due to the Executive under this Agreement, the Company shall continue such payments to the Executive&#146;s beneficiary designated in writing to the Company prior to the Executive&#146;s death (or to the
Executive&#146;s estate, if the Executive fails to make such designation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Enforceability</U>. If any
portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of
this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid
and enforceable to the fullest extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>. The provisions of this Agreement
shall survive the termination of this Agreement and/or the termination of the Executive&#146;s employment to the extent necessary to effectuate the terms contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver</U>. No waiver of any provision hereof shall be effective unless made in writing and signed by the
waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be
deemed a waiver of any subsequent breach. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. Any notices, requests, demands and other
communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to
the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>. This Agreement may be amended or modified only by a written instrument signed by the Executive
and by a duly authorized representative of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect on Other Plans and Agreements</U>. An
election by the Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company&#146;s benefit
plans, programs or policies. Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company&#146;s benefit plans, programs or policies except as otherwise provided in Section&nbsp;8 hereof, and except that the
Executive shall have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise. In the event that the Executive is party to an agreement with the Company providing for payments or benefits under such plan or
agreement and under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section&nbsp;5 and Section&nbsp;6 of this Agreement are mutually exclusive and in no
event shall the Executive be entitled to payments or benefits pursuant to both Section&nbsp;5 and Section&nbsp;6 of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. This is a California contract and shall be construed under and be governed in all respects by
the laws of the State of California, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and
applied by the United States Court of Appeals for the 9<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Circuit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions</U>. Notwithstanding anything to the contrary herein, the effectiveness of this Agreement shall be
conditioned on (i)&nbsp;the Executive&#146;s satisfactory completion of reference and background checks, if so requested by the Company, and (ii)&nbsp;the Executive&#146;s submission of satisfactory proof of the Executive&#146;s legal authorization
to work in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be executed in any number of
counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective
Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ADICET THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chen Schor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chen Schor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>DON HEALEY</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Don Healey</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Don Healey</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d71827dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g71827img1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Adicet Appoints Don Healey, Ph.D., as Chief Technology Officer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Menlo Park, CA and Boston, MA &#150; October&nbsp;26, 2020 &#150; Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Don Healey, Ph.D., as Chief Technology Officer.
Dr.&nbsp;Healey will lead the development of Adicet&#146;s genetically-modified T cell therapies for clinical development and commercialization, including manufacturing, viral vector operations and analytics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited to welcome Don as a new member of Adicet&#146;s Executive Leadership Team,&#148; said Chen Schor, President and Chief Executive Officer
of Adicet. &#147;Don&#146;s expertise in guiding the production and release of cell therapy products, as well as his deep knowledge of the scientific, technical, and strategic approaches to genetically modifying, characterizing and scaling the
production of such cell products is a valuable addition to the growth of Adicet as we continue to advance our pipeline of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;off-the-shelf&#148;</FONT></FONT> gamma delta T cell
product candidates.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am honored to join the Adicet team, and look forward to helping guide the development of
<FONT STYLE="white-space:nowrap">ADI-001</FONT> through the next stages of development and registration,&#148; said Dr.&nbsp;Healey. &#147;I am very excited by the potential of Adicet&#146;s gamma delta T cell platform and its novel targeting
approaches. Adicet&#146;s platforms and product candidates are highly differentiated and may provide oncology patients with selective tumor targeting, innate and adaptive anti-tumor immune response, and improved persistence for durable
activity.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Healey has nearly two decades of experience in cell therapy development and manufacturing. Dr.&nbsp;Healey joins Adicet most
recently from KBI Biopharma Inc., a biopharmaceutical contract services organization, where he was responsible for establishing process development, manufacturing, quality control and facilities management for biopharmaceutical clients developing
cellular therapies. Previously, he served as Chief Scientific Officer at Opexa Therapeutics, Inc., where he was responsible for all <FONT STYLE="white-space:nowrap">pre-clinical</FONT> scientific development, closed-system process design and the
scaling of Opexa&#146;s autologous <FONT STYLE="white-space:nowrap">T-cell</FONT> immunotherapy. Dr.&nbsp;Healey has also served as Director of Immunology at Argos Therapeutics Inc. and Group leader for Immunology at ML Laboratories, UK, (formerly
Cobra Biotherapeutics). Dr.&nbsp;Healey received his Ph.D. from University of London, and holds a B.Sc. in Cellular Pathology from Bristol University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Adicet </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adicet is a biotechnology company
discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;off-the-shelf&#148;</FONT></FONT> gamma delta
T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in
patients.&nbsp;For more information, please visit our website at&nbsp;http://www.adicetbio.com. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g71827img1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995
relating to business and operations of Adicet including, but not limited to, preclinical and clinical development of Adicet&#146;s product candidates, including future plans or expectations for <FONT STYLE="white-space:nowrap">ADI-001</FONT> and
potential therapeutic effects of <FONT STYLE="white-space:nowrap">ADI-001.</FONT> Any forward-looking statements in this press release are based on management&#146;s current expectations and beliefs of future events, and are subject to a number of
risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of
<FONT STYLE="white-space:nowrap">COVID-19</FONT> on Adicet&#146;s business and financial results, including with respect to disruptions to our clinical trials, business operations, employee hiring and retention, and ability to raise additional
capital; Adicet&#146;s ability to execute on its strategy; Adicet&#146;s ability to meet production and product release expectations; as well as those risks and uncertainties set forth in the company&#146;s most recent annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and subsequent filings with the&nbsp;Securities and Exchange Commission.&nbsp;For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet&#146;s
actual results to differ from those contained in the forward-looking statements, see the section entitled &#147;Risk Factors&#148; in Adicet&#146;s most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and our periodic
reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the&nbsp;SEC, as well as discussions of potential risks, uncertainties, and other important factors in Adicet&#146;s other
filings with the&nbsp;SEC. All information in this press release is as of the date of the release, and&nbsp;Adicet undertakes no duty to update this information unless required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor and Media Contacts </B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anne Bowdidge </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">abowdidge@adicetbio.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Janhavi Mohite </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stern Investor Relations, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">212-362-1200</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">janhavi.mohite@sternir.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>acet-20201026.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-6 Build:20200922.5 -->
<!-- Creation date: 10/26/2020 11:58:49 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:acet="http://www.adicetbio.com/20201026"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.adicetbio.com/20201026"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acet-20201026_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acet-20201026_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>acet-20201026_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-6 Build:20200922.5 -->
<!-- Creation date: 10/26/2020 11:58:49 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>acet-20201026_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-6 Build:20200922.5 -->
<!-- Creation date: 10/26/2020 11:58:49 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="acet-20201026.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g71827img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g71827img1.jpg
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M!"4      !#\X1^)R+?)>"\T8C0'6'?K_^X #D%D;V)E &3      ?_; (0
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0("
M @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\  $0@
M(P"O P$1  (1 0,1 ?_$ *(   ,! 0$! 0             ("0H'!@4+ 0 !
M! ,! 0               P0%!@$"!PD($   !@(!! $# P(%!0     ! @,$
M!08'" D $1(3%"$5"B(6%S$C022W&#A10B4F>!$  0($! 0#!@0$!04
M 0(# !$$!2$Q$@9!41,'82(4<8&1,D((H;$5%L%2<B/PT>%BHC-#)#0)_]H
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M\LU*(ON+[M5<ATF>1%Q#6RF3T99*])I%,)%!9RT0Y=LEC(J )3E _DF<!*8
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>#H@@Z((.B"#H@@Z((.B"#H@@Z((.B"#H@@Z((__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d71827d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="acet-20201026.xsd" xlink:type="simple"/>
    <context id="duration_2020-10-26_to_2020-10-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2020-10-26</startDate>
            <endDate>2020-10-26</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2020-10-26_to_2020-10-26">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2020-10-26_to_2020-10-26"
      id="Hidden_dei_EntityCentralIndexKey">0001720580</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2020-10-26_to_2020-10-26">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2020-10-26_to_2020-10-26">2020-10-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2020-10-26_to_2020-10-26">Adicet Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2020-10-26_to_2020-10-26">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2020-10-26_to_2020-10-26">001-38359</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2020-10-26_to_2020-10-26">81-3305277</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2020-10-26_to_2020-10-26">500 Boylston Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2020-10-26_to_2020-10-26">13th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2020-10-26_to_2020-10-26">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2020-10-26_to_2020-10-26">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2020-10-26_to_2020-10-26">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2020-10-26_to_2020-10-26">(857)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2020-10-26_to_2020-10-26">315-5528</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2020-10-26_to_2020-10-26">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2020-10-26_to_2020-10-26">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2020-10-26_to_2020-10-26">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2020-10-26_to_2020-10-26">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2020-10-26_to_2020-10-26">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2020-10-26_to_2020-10-26">ACET</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2020-10-26_to_2020-10-26">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2020-10-26_to_2020-10-26">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2020-10-26_to_2020-10-26">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139953766353496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 26, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001720580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 26,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adicet Bio, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3305277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Boylston Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">13th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">315-5528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACET<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M%     @ 081:48.II0/4 0  ,@8   T   !X;"]S='EL97,N>&ULU57;BM1
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 081:41PX9>H_ 0  / (
M  \   !X;"]W;W)K8F]O:RYX;6R-4<MNPD ,_)75?D 34(M41+B4/I"J%I6*
M^Y)UB,4^(J\#+5]?)U%4I%YZ\GILC6=F%^=(QWV,1_7E74B%KIF;>9:EL@9O
MTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S!H)>+D6M#V743&4K&& 3L@!W"
M.?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4Q_-+)+S$P,9M2XK.%7HR#'9
MC.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CYC6@\@2P/7<OQ"1T#K0S#,\6V
MP7#H:,1%=F6CSV&L0XAS^D^,L:JPA%4L6P^!AQP)7"<PI!J;I%4P'@H]KB@3
MK'H,+"&I=1BH9+=S*J?7=G#-(O<J0YJC#&AM!^&C6@L5!K!O<B )+LF5&U)=
MZ7FFMW>3>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( $&$6E$D'INBK0
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 081:4>YJL]/N    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M081:49E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " !!A%I1A3>,<&$$  !W$0  &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M081:48.II0/4 0  ,@8   T              ( !I P  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " !!A%I1EXJ[',     3 @  "P              @ &C
M#@  7W)E;',O+G)E;'-02P$"% ,4    " !!A%I1'#AEZC\!   \ @  #P
M            @ &,#P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 081:
M420>FZ*M    ^ $  !H              ( !^!   'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ 081:4660>9(9 0  SP,  !,
M         ( !W1$  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^
) @  )Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d71827d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d71827d8k.htm">d71827d8k.htm</File>
    <File>acet-20201026.xsd</File>
    <File>acet-20201026_lab.xml</File>
    <File>acet-20201026_pre.xml</File>
    <File>d71827dex991.htm</File>
    <File>d71827dex992.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d71827d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d71827d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "acet-20201026_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acet-20201026_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "acet-20201026.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "acet",
   "nsuri": "http://www.adicetbio.com/20201026",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d71827d8k.htm",
      "contextRef": "duration_2020-10-26_to_2020-10-26",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d71827d8k.htm",
      "contextRef": "duration_2020-10-26_to_2020-10-26",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adicetbio.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-20-276994-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-276994-xbrl.zip
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M]7-,-@>YNXD'OKUJ%P[^_ =02P,$%     @ 081:4=';R1"T!@  /$H  !4
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M/=R5PT,%T"60U@TN^C8L&ZR;Q\/YD@5<++E(;JK<QFJ(QGRE%B_;,0]KTGU
MJE78[6QRZY3FHV ACSL9.P4AJ0A92= UD4;E._@R3,[3S>&-T@6-R*?58DI$
MO;DIYK4Z) 8#W'R\.?Z/M7!9U^J0RB-AC=VO@6&KIO%PG?B;RU MHN@=36^I
M/X7=4I%603YDC5L$-T>\4AB7=U4*=FOATN_4BF$4GN ';S!.PU#9D-E_5Y21
M0;VA, JT.A!5EOB!P.:#4"J*.P29_JM\ W0EN&98*QMG-@P#\ 0O+@=@V'0
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MP<V8D<H6<CH&WO9*1,&_;ZN#*8A-&NXXG1YK:T=4M+7-L*.B0DBJ(AL.#_<
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M=Q\%DT/\9]%@3$'A7Z4^*EE2\K$L7))4'-/8\>@[ !'ZW>*D12!B#;8J1F'
M5N8YN@OHVL:@;6=,'$YCVN5@L1D#_@Y?R3@A $Q^5%>ZM))I(@IX0 U'DC!
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M6L"F=QSW/U9YIM=,/.6B.]$S)^)]-1ZS:=8JP7O811[0)."\C=#[TG*Z]5A
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MF-5]&+B148#)#X*R%4;C9JH@F*UCM/2;T$K.W+_XL^YJF(B2G4R $C9W:UN
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M0V<JHTFQWH0JXU,G5(MM)F0&Y 67A"+7T=Q3WMIJFWA'_="[]G:3&]%LE=_
MR,</8HG'U6 JUS/Y@> MD(9TUVWO[-8U_EP-AG-7/&8>+#P\6'U+#7 Z^;1C
M%._E=I?Q,R\BQ@#_1.6^%'O]^W@:*I,MNL=^N)+5GQ4_L0@R&X:\ EZ%*KR!
MTXFT6_BT,!X?%//JY/=$OV&W!KE*KBZN,<EO%TD$&[ASN MZ!^*;/?$&825"
MTA9LG(C8_N* ['?_*Z\M?6_K(C^0HU4Z>9L]C^R6&QB?@CY2B1OMB;3RBPJ'
ML0F'+5[HAU][\0H>FV]%E,B&^OO8YUT2_-0P]%N<B1^C%JHN-B''E*PUP$SX
ME FD<&&<+L(R8S6A+XY?9Q]M.C$FEA2*JF]Y=L*VY]0-V>^\*1W5I2LV-T"6
M;(,@UCG3WE':^"+*GO/J?& 'F$R:$G"Z\T#%A"V"^H9*)E"<,EG6OJ^YG6+1
M2H;R0O(W?ACVO]\6;VKKN&M1%5TSFU7M8IOF<1Z[#' TI;R2*%XD(6]G?XV4
M#'MF9NQQU,D2M-3\>^#JPT%_QP@E;MQ5F,P'^+C94QLJ;&^)5"3 HKZM4..@
MQ&\_8W-[:8;K.CZ ^%BQZ21C>=3AE:S3[1S;L(XT+;M5?;A5D1<[C;.W+$[1
M.4TMH:BFKJEPPWZ==F*N%&V@.JS^TNW EA/X4:0T?8XD9G]R6 H@^%/@:C:E
ME*_1CR2;Q/4E7+S %A#6QA/VCI)F8D_;GHPQMOVI.I[*#:&VN\1#DY% *F]*
MW@Z,T1U>7B^B/9CBCM=V"Q_)LX5B7<8 _@X<<>V-6_$!)AK>S 7TZO<4L6:0
MW) 6MNGP-;0) A5Z$CG/P.QQJ(H2IPB7.HT+7H2\_T,Y]2Y:H>/QD.*$G4&3
M*IN;"+Z ?;BZ-WH;2O_$>/.>DEM=Q91$1W=1@3+BK2KS,@Y,S>=N,GI8!#KL
MJJR*,!H?XQE[:XP;F0_<:_A3HBCWZR/[LA'=@ *8E8TFP+PH-F"'U$^_*U4K
M3F"@SAC"E<U*<C(#MFZ*&&&3Q<^K8G2PLPQ+&'W3*S)<"QUW&V%'AE&QV),Q
M<[#\D]?75+(HC:Q257\5^5$";M=3=S?2]LWIQI>CB;6:9Y=-V6B)+4':XYZ8
M6WZX5;G(C]N-T\BXL&RTNB[%DI*D/Y;?+N:<OGVSU8*W+;8ELF939^G,G-*7
M+<DURM"V*<KEDQ%EPSLJ\F8O]=[%=TY^]*&X%"D'18@X\SU7+[Y0E/[%M9$Y
M1WCK$^&A\MQ4F 8MK<DEX=+/,/ 3Q&US:"(B/["XJ\8X(C'U<SS;-2DUG;V_
MN)\ V3=H%GSA*?NK^ ,U50XZDDC%+G+(2%EOYA%D*A; #X#72/.H3H)LZ6<S
M"@QN0/%N#38O_[URDJYSG_L1DVW#XLEJ2$O6Y*B:."X*RSBPG".1:?NCV[:
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M4$L! A0#%     @ 081:4=';R1"T!@  /$H  !4              ( !E0,
M &%C970M,C R,#$P,C9?;&%B+GAM;%!+ 0(4 Q0    ( $&$6E&$,YC=XP0
M )DN   5              "  7P*  !A8V5T+3(P,C Q,#(V7W!R92YX;6Q0
M2P$"% ,4    " !!A%I19O5ESOD2   8=   #0              @ &2#P
M9#<Q.#(W9#AK+FAT;5!+ 0(4 Q0    ( $&$6E'YH;4FC3T  !T- 0 0
M          "  ;8B  !D-S$X,C=D97@Y.3$N:'1M4$L! A0#%     @ 081:
M41P<2W;C"@  =2$  !               ( !<6   &0W,3@R-V1E>#DY,BYH
8=&U02P4&      8 !@!\ 0  @FL

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
